Craig Johnson has served on the board of directors for seven biotech companies in total, six public and one private. He currently serves on the board of Mirati Therapeutics, Heron Therapeutics, Odonate Therapeutics, and La Jolla Pharmaceuticals, and he previously served on the board of Ardea Biosciences, Adamis Pharmaceuticals and GenomeDx Biosciences. Prior to his board activities, Craig was CFO for a number of biotech companies. Earlier in his career, he practiced as a CPA with Price Waterhouse in Detroit and San Diego, and he received a B.B.A. degree from the University of Michigan-Dearborn.